[Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission]
Clicks: 274
ID: 117028
2017
The arrival of new drugs and new therapeutic strategies allowed to reach sustained remission in an increasing number of patients with rheumatoid arthritis. The study of biologic disease-modifying anti-rheumatic drugs (bDMARDs) adaptation strategies is a need to optimize the benefit/risk balance and …
| Reference Key |
a2017la[discontinuation
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mallick A;Fautrel B;Sagez F;Sordet C;Javier RM;Petit H;Chatelus E;Rahal N;Gottenberg JE;Sibilia J;; |
| Journal | la revue de medecine interne |
| Year | 2017 |
| DOI | DOI not found |
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
Recurrence
Remission Induction
dose-response relationship
drug
arthritis
rheumatoid / drug therapy*
practice patterns
antirheumatic agents / administration & dosage*
pmid:28161110
doi:10.1016/j.revmed.2016.12.014
a mallick
b fautrel
j sibilia
biological factors / administration & dosage
biological products / administration & dosage*
physicians'
withholding treatment* / standards
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.